Literature DB >> 21224831

An evolved adeno-associated viral variant enhances gene delivery and gene targeting in neural stem cells.

Jae-Hyung Jang1, James T Koerber, Jung-Suk Kim, Prashanth Asuri, Tandis Vazin, Melissa Bartel, Albert Keung, Inchan Kwon, Kook In Park, David V Schaffer.   

Abstract

Gene delivery to, and gene targeting in, stem cells would be a highly enabling technology for basic science and biomedical application. Adeno-associated viral (AAV) vectors have demonstrated the capacity for efficient delivery to numerous cells, but their application to stem cells has been limited by low transduction efficiency. Due to their considerable advantages, however, engineering AAV delivery systems to enhance gene delivery to stem cells may have an impact in stem cell biology and therapy. Therefore, using several diverse AAV capsid libraries-including randomly mutagenized, DNA shuffled, and random peptide insertion variants-we applied directed evolution to create a "designer" AAV vector with enhanced delivery efficiency for neural stem cells (NSCs). A novel AAV variant, carrying an insertion of a selected peptide sequence on the surface of the threefold spike within the heparin-binding site, emerged from this evolution. Importantly, this evolved AAV variant mediated efficient gene delivery to rat, mouse, and human NSCs, as well as efficient gene targeting within adult NSCs, and it is thus promising for applications ranging from basic stem cell biology to clinical translation.

Entities:  

Mesh:

Year:  2011        PMID: 21224831      PMCID: PMC3070092          DOI: 10.1038/mt.2010.287

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  48 in total

Review 1.  Gene therapy: twenty-first century medicine.

Authors:  Inder M Verma; Matthew D Weitzman
Journal:  Annu Rev Biochem       Date:  2005       Impact factor: 23.643

2.  Efficient photoreceptor-targeted gene expression in vivo by recombinant adeno-associated virus.

Authors:  J G Flannery; S Zolotukhin; M I Vaquero; M M LaVail; N Muzyczka; W W Hauswirth
Journal:  Proc Natl Acad Sci U S A       Date:  1997-06-24       Impact factor: 11.205

3.  Fibroblast growth factor-2 activates a latent neurogenic program in neural stem cells from diverse regions of the adult CNS.

Authors:  T D Palmer; E A Markakis; A R Willhoite; F Safar; F H Gage
Journal:  J Neurosci       Date:  1999-10-01       Impact factor: 6.167

4.  Highly efficient endogenous human gene correction using designed zinc-finger nucleases.

Authors:  Fyodor D Urnov; Jeffrey C Miller; Ya-Li Lee; Christian M Beausejour; Jeremy M Rock; Sheldon Augustus; Andrew C Jamieson; Matthew H Porteus; Philip D Gregory; Michael C Holmes
Journal:  Nature       Date:  2005-04-03       Impact factor: 49.962

5.  Optimization of DNA shuffling for high fidelity recombination.

Authors:  H Zhao; F H Arnold
Journal:  Nucleic Acids Res       Date:  1997-03-15       Impact factor: 16.971

6.  Human gene targeting by viral vectors.

Authors:  D W Russell; R K Hirata
Journal:  Nat Genet       Date:  1998-04       Impact factor: 38.330

7.  Gene targeting in stem cells from individuals with osteogenesis imperfecta.

Authors:  Joel R Chamberlain; Ulrike Schwarze; Pei-Rong Wang; Roli K Hirata; Kurt D Hankenson; James M Pace; Robert A Underwood; Kit M Song; Michael Sussman; Peter H Byers; David W Russell
Journal:  Science       Date:  2004-02-20       Impact factor: 47.728

8.  Second-strand synthesis is a rate-limiting step for efficient transduction by recombinant adeno-associated virus vectors.

Authors:  F K Ferrari; T Samulski; T Shenk; R J Samulski
Journal:  J Virol       Date:  1996-05       Impact factor: 5.103

9.  Random peptide libraries displayed on adeno-associated virus to select for targeted gene therapy vectors.

Authors:  Oliver J Müller; Felix Kaul; Matthew D Weitzman; Renata Pasqualini; Wadih Arap; Jürgen A Kleinschmidt; Martin Trepel
Journal:  Nat Biotechnol       Date:  2003-08-03       Impact factor: 54.908

10.  Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain.

Authors:  M G Kaplitt; P Leone; R J Samulski; X Xiao; D W Pfaff; K L O'Malley; M J During
Journal:  Nat Genet       Date:  1994-10       Impact factor: 38.330

View more
  34 in total

1.  A revisited folding reporter for quantitative assay of protein misfolding and aggregation in mammalian cells.

Authors:  Simpson Gregoire; Inchan Kwon
Journal:  Biotechnol J       Date:  2012-06-27       Impact factor: 4.677

Review 2.  E Pluribus Unum: 50 Years of Research, Millions of Viruses, and One Goal--Tailored Acceleration of AAV Evolution.

Authors:  Dirk Grimm; Sergei Zolotukhin
Journal:  Mol Ther       Date:  2015-09-21       Impact factor: 11.454

3.  Adeno-Associated Virus-Based Gene Therapy for Lifelong Correction of Genetic Disease.

Authors:  Christian M Brommel; Ashley L Cooney; Patrick L Sinn
Journal:  Hum Gene Ther       Date:  2020-08-21       Impact factor: 5.695

Review 4.  The AAV vector toolkit: poised at the clinical crossroads.

Authors:  Aravind Asokan; David V Schaffer; R Jude Samulski
Journal:  Mol Ther       Date:  2012-01-24       Impact factor: 11.454

5.  Advances in homology directed genetic engineering of human pluripotent and adult stem cells.

Authors:  Kalpith Ramamoorthi; Donald Curtis; Prashanth Asuri
Journal:  World J Stem Cells       Date:  2013-10-26       Impact factor: 5.326

6.  Viral Vectors, Animal Models, and Cellular Targets for Gene Therapy of Cystic Fibrosis Lung Disease.

Authors:  Yinghua Tang; Ziying Yan; John F Engelhardt
Journal:  Hum Gene Ther       Date:  2020-04-15       Impact factor: 5.695

Review 7.  Engineering adeno-associated viruses for clinical gene therapy.

Authors:  Melissa A Kotterman; David V Schaffer
Journal:  Nat Rev Genet       Date:  2014-05-20       Impact factor: 53.242

8.  CFTR gene transfer with AAV improves early cystic fibrosis pig phenotypes.

Authors:  Benjamin Steines; David D Dickey; Jamie Bergen; Katherine Jda Excoffon; John R Weinstein; Xiaopeng Li; Ziying Yan; Mahmoud H Abou Alaiwa; Viral S Shah; Drake C Bouzek; Linda S Powers; Nicholas D Gansemer; Lynda S Ostedgaard; John F Engelhardt; David A Stoltz; Michael J Welsh; Patrick L Sinn; David V Schaffer; Joseph Zabner
Journal:  JCI Insight       Date:  2016-09-08

9.  Controlling AAV Tropism in the Nervous System with Natural and Engineered Capsids.

Authors:  Michael J Castle; Heikki T Turunen; Luk H Vandenberghe; John H Wolfe
Journal:  Methods Mol Biol       Date:  2016

10.  The nontoxic cell cycle modulator indirubin augments transduction of adeno-associated viral vectors and zinc-finger nuclease-mediated gene targeting.

Authors:  Shamim H Rahman; Sylwia Bobis-Wozowicz; Debanjana Chatterjee; Katharina Gellhaus; Kaweh Pars; Regine Heilbronn; Roland Jacobs; Toni Cathomen
Journal:  Hum Gene Ther       Date:  2012-12-10       Impact factor: 5.695

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.